Nurix Therapeutics, Inc. Common stock NRIX
i
Market dataready · fetched 2026-11-12T03:15:12.721Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:37:26.159678619Z
FundamentalsSEC EDGAR · ready · as of 2026-08-31 · fetched 2026-11-12T03:15:12.346756+00:00
Nurix Therapeutics, Inc. Common stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 11.56 | 547.4% | 45.1% | |||
| 25Δ | 20.99 | 188.7% | 31.0% | 13.71 | 220.5% | 22.8% |
| 30Δ | 19.73 | 170.3% | 23.9% | 14.47 | 198.6% | 18.9% |
| 35Δ | 18.56 | 148.3% | 17.3% | 15.23 | 176.7% | 15.0% |
| 40Δ | 15.99 | 154.8% | 11.1% | |||
| 45Δ | 16.85 | 71.4% | 5.8% | 16.49 | 152.5% | 9.6% |
| 50Δ | 16.61 | 72.5% | 5.1% | 16.98 | 150.3% | 8.1% |
| 55Δ | 16.37 | 73.5% | 4.4% | 17.60 | 158.2% | 7.2% |
| 60Δ | 16.14 | 74.6% | 3.7% | 18.22 | 163.2% | 6.3% |
| 65Δ | 15.91 | 73.7% | 3.1% | 18.83 | 162.3% | 5.2% |
| 70Δ | 15.69 | 70.1% | 2.5% | 19.70 | 169.6% | 4.3% |
| 75Δ | 15.48 | 66.6% | 2.0% | 22.27 | 226.8% | 4.3% |
| 80Δ | 15.27 | 63.1% | 1.4% | 25.32 | 263.7% | 3.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.56
- IV
- 547.4%
- B/E move
- 45.1%
25Δ
- Pseudo strike
- 20.99
- IV
- 188.7%
- B/E move
- 31.0%
- Pseudo strike
- 13.71
- IV
- 220.5%
- B/E move
- 22.8%
30Δ
- Pseudo strike
- 19.73
- IV
- 170.3%
- B/E move
- 23.9%
- Pseudo strike
- 14.47
- IV
- 198.6%
- B/E move
- 18.9%
35Δ
- Pseudo strike
- 18.56
- IV
- 148.3%
- B/E move
- 17.3%
- Pseudo strike
- 15.23
- IV
- 176.7%
- B/E move
- 15.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.99
- IV
- 154.8%
- B/E move
- 11.1%
45Δ
- Pseudo strike
- 16.85
- IV
- 71.4%
- B/E move
- 5.8%
- Pseudo strike
- 16.49
- IV
- 152.5%
- B/E move
- 9.6%
50Δ
- Pseudo strike
- 16.61
- IV
- 72.5%
- B/E move
- 5.1%
- Pseudo strike
- 16.98
- IV
- 150.3%
- B/E move
- 8.1%
55Δ
- Pseudo strike
- 16.37
- IV
- 73.5%
- B/E move
- 4.4%
- Pseudo strike
- 17.60
- IV
- 158.2%
- B/E move
- 7.2%
60Δ
- Pseudo strike
- 16.14
- IV
- 74.6%
- B/E move
- 3.7%
- Pseudo strike
- 18.22
- IV
- 163.2%
- B/E move
- 6.3%
65Δ
- Pseudo strike
- 15.91
- IV
- 73.7%
- B/E move
- 3.1%
- Pseudo strike
- 18.83
- IV
- 162.3%
- B/E move
- 5.2%
70Δ
- Pseudo strike
- 15.69
- IV
- 70.1%
- B/E move
- 2.5%
- Pseudo strike
- 19.70
- IV
- 169.6%
- B/E move
- 4.3%
75Δ
- Pseudo strike
- 15.48
- IV
- 66.6%
- B/E move
- 2.0%
- Pseudo strike
- 22.27
- IV
- 226.8%
- B/E move
- 4.3%
80Δ
- Pseudo strike
- 15.27
- IV
- 63.1%
- B/E move
- 1.4%
- Pseudo strike
- 25.32
- IV
- 263.7%
- B/E move
- 3.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 83.81% | |
| 84.05% | |
| 87.29% | |
| 86.62% | |
| 84.11% | |
| 87.78% | |
| 91.00% | |
| 88.44% | |
| 95.09% | |
| 89.48% |
Biotechnology
NRXP
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders…
More →NRXS
NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.
More →NTLA
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
More →NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
More →NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs.…
More →NVCT
Description unavailable
More →